Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO.
Ralf‐Dieter Hofheinz(University of Mannheim), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Nils Homann(Fraunhofer Project Centre Wolfsburg), Eray Goekkurt(Sorbonne Université), Georg Martin Haag(Heidelberg University), Matthias Ebert(University of Mannheim), Michael A. Rieger(Goethe University Frankfurt), Volker Hagen(St.-Johannes-Hospital Dortmund), Thomas Hoehler(Johannes Gutenberg University Mainz), Gerrit zur Hausen(Goethe University Frankfurt), Peter Reichardt(Helios Hospital Berlin-Buch), Thomas J. Ettrich(Universität Ulm), K Borchert(University Hospital Magdeburg), Udo Lindig(Jena University Hospital), Wolff Schmiegel(Universitätsklinikum Knappschaftskrankenhaus Bochum), Michael Koenigsmann, Albrecht Kretzschmar(Roche (Switzerland)), Christian Teschendorf(St. Josefs Hospital), Hendrik Kroening, Claudia Pauligk(Goethe University Frankfurt)
Cited by 12
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k